NYSEARCA:APUS - NYSE Arca - US03771D1028 - Common Stock - Currency: USD
NYSEARCA:APUS (7/17/2025, 8:04:04 PM)
1.79
-0.01 (-0.56%)
The current stock price of APUS is 1.79 USD. In the past month the price decreased by -2.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.64 | 338.09B | ||
AMGN | AMGEN INC | 14.37 | 160.37B | ||
GILD | GILEAD SCIENCES INC | 14.06 | 135.34B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.97B | ||
REGN | REGENERON PHARMACEUTICALS | 12.41 | 59.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.34B | ||
ARGX | ARGENX SE - ADR | 99.6 | 34.97B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.42B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.69B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.52B | ||
INSM | INSMED INC | N/A | 19.76B | ||
NTRA | NATERA INC | N/A | 19.58B |
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
APIMEDS PHARMACEUTICALS US I
25 Edinburg Circle
Matawan NEW JERSEY US
Employees: 2
Phone: 18082097887
The current stock price of APUS is 1.79 USD. The price decreased by -0.56% in the last trading session.
The exchange symbol of APIMEDS PHARMACEUTICALS US I is APUS and it is listed on the NYSE Arca exchange.
APUS stock is listed on the NYSE Arca exchange.
APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 20.73M USD. This makes APUS a Nano Cap stock.
APIMEDS PHARMACEUTICALS US I (APUS) currently has 2 employees.
APIMEDS PHARMACEUTICALS US I (APUS) has a support level at 1.64 and a resistance level at 1.83. Check the full technical report for a detailed analysis of APUS support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
APUS does not pay a dividend.
The outstanding short interest for APIMEDS PHARMACEUTICALS US I (APUS) is 0.06% of its float. Check the ownership tab for more information on the APUS short interest.
ChartMill assigns a technical rating of 3 / 10 to APUS.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |